On best practices: the Institute of Medicine scheme for developing, validating, and demonstrating clinical utility of omics-based diagnostic and predictive tests

Gilbert S Omenn

doi:10.1002/prca.201300041

On best practices: the Institute of Medicine scheme for developing, validating, and demonstrating clinical utility of omics-based diagnostic and predictive tests

Proteomics Clin Appl. 2013 Dec;7(11-12):748-55. doi: 10.1002/prca.201300041.

Author

Gilbert S Omenn¹

Affiliation

¹ Departments of Computational Medicine and Bioinformatics, Internal Medicine, and Human Genetics, School of Public Health, University of Michigan, Ann Arbor, MI, USA; Institute for Systems Biology, Seattle, WA, USA.

PMID: 24323457
DOI: 10.1002/prca.201300041

Abstract

The Institute of Medicine of the US National Academy of Sciences issued a major report in 2012 that provides important guidance for the proteomics community for credible and transparent development of all kinds of omics-based diagnostic and prognostic tests. The key elements are summarized here to provide a compass that can guide the studies emerging from many laboratories as reported in this special issue of Proteomics Clinical Applications on "Diagnostic Proteomics."

Keywords: Diagnostics; Institute of Medicine; Omics; Tests.

MeSH terms

Humans
National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division
Proteomics / methods*
United States